

CLAIMS

1. An antibody or binding fragment specific to the FBG domain of tenascin C, comprising:
a VH region in which CDRH1 is SEQ ID NO: 9, CDRH2 is SEQ ID NO: 10, and
CDRH3 is independently selected from SEQ ID NO: 11, 30, 32, 34, 36, 38, 40, 42, 44
5 and 46, and
a VL region in which a CDRL1 is SEQ ID NO: 5, CDRL2 is SEQ ID NO: 13 and
CDRL3 is SEQ ID NO: 14.
2. An antibody or binding fragment according to Claim 1, in which CDRH3 is SEQ ID
NO: 11.
- 10 3. An antibody or binding fragment according to Claim 2, in which the VH region has a
sequence shown in SEQ ID NO: 12.
4. An antibody or binding fragment according to Claim 1, in which CDH3 is SEQ ID NO:
30.
5. An antibody or binding fragment according to Claim 4, in which the VH region has a
15 sequence shown in SEQ ID NO: 31.
6. An antibody or binding fragment according to Claim 1, in which CDH3 is SEQ ID NO:
34.
7. An antibody or binding fragment according to Claim 6, in which the VH region has a
sequence shown in SEQ ID NO: 35.
- 20 8. An antibody or binding fragment according to Claim 1, in which CDH3 is SEQ ID NO:
36.
9. An antibody or binding fragment according to Claim 8, in which the VH region has a
sequence shown in SEQ ID NO: 37.
10. An antibody or binding fragment according to Claim 1, in which CDH3 is SEQ ID NO:
25 38.
11. An antibody or binding fragment according to Claim 10, in which the VH region has a
sequence shown in SEQ ID NO: 39.

12. An antibody or binding fragment according to Claim 1, in which CDH3 is SEQ ID NO: 42.
13. An antibody or binding fragment according to Claim 12, in which the VH region has a sequence shown in SEQ ID NO: 43.
- 5 14. An antibody or binding fragment according to any preceding claim, in which the VL region has a sequence shown in SEQ ID NO: 15.
15. An antibody or binding fragment according to any preceding claim, in which the antibody or binding fragment is humanised or fully human.
16. A composition comprising an antibody or binding fragment according to any preceding
10 claim and a pharmaceutically acceptable carrier, excipient and/or diluent.
17. A composition according to Claim 16, in which composition further comprises an agent selected from the group consisting of: an anti-inflammatory agent, such as non-steroidal anti-inflammatories (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and immunosuppressants; a statin; a biological agent; an immunosuppressive
15 agent, a salicylate and a microbicidal agent.
18. Use of an antibody or binding fragment according to any of Claims 1 to 15 or a composition according to Claim 16 or 17 in the manufacture of a medicament for use in the treatment of a chronic inflammatory condition.
19. Use according to Claim 18, in which the chronic inflammatory response is associated
20 with rheumatoid arthritis (RA) ; autoimmune conditions; inflammatory bowel diseases; such as Crohn's disease and ulcerative colitis; non-healing wounds; multiple sclerosis; cancer; atherosclerosis; sjogrens disease; diabetes; lupus erythrematosus, such as systemic lupus erythrematosus; asthma; fibrotic diseases, such as liver cirrhosis, pulmonary fibrosis, UV damage, psoriasis, ankylosing spondylitis and cardiovascular disease.
- 25 20. Use according to Claim 19, in which the chronic inflammatory response is associated with rheumatoid arthritis (RA).